Targeting Beta-1 Integrin Suppresses Invasive Recurrence in a 3-dimensional Model of Radiation Treated Ductal Carcinoma In situ

Abstract

DCIS (ductal carcinoma in situ) is comprised of cancerous cells that are contained within the milk duct and separated from the stroma by a basement membrane. Akt activation is implicated in breast cancer progression and also upregulated in ∼30% of DCIS lesions. We have previously shown that β1-integrin inhibition enhanced the efficacy of IR in invasive breast cancer, via an Akt-mediated effect. Radiation therapy (RT) is commonly used to treat DCIS, resulting in a decrease in recurrence risk by ∼50%.